基于免疫抑制性受体的血液肿瘤靶向免疫治疗研究  

Advance in targeted immunotherapy for hematological malignancies based on immunosuppressive receptors

作　　者：陈少华[1] 查显丰[2] 李扬秋[1,3] 

机构地区：[1]暨南大学医学院血液研究所,广州510632 [2]暨南大学第一附属医院临床实验室 [3]暨南大学再生医学教育部重点实验室

出　　处：《白血病．淋巴瘤》2015年第8期449-452,共4页Journal of Leukemia & Lymphoma

基　　金：基金项目：国家自然科学基金（81100353、81270604、81400109、81570143）

摘　　要：T细胞免疫功能缺陷导致多数血液肿瘤患者不能产生有效的抗肿瘤免疫应答,从而逃避宿主免疫系统的攻击,即肿瘤细胞免疫逃逸.近年来认为肿瘤免疫抑制最为重要的机制之一是CD8＋T细胞的功能耗竭,主要为免疫细胞异常表达程序性死亡分子1（PD-1）和细胞毒性T淋巴细胞相关抗原（CTLA-4）等免疫抑制所介导,而阻断此通路可以使T细胞部分或全部恢复功能.文章介绍近年来血液肿瘤中PD-1和CTLA-4及二者在介导T细胞免疫耐受中的作用及其在靶向治疗研究中的进展,为血液肿瘤的免疫靶向治疗提供新的思路.T cell immune deficiency results in inefficient anti-tumor immune response in most patients with hematological malignancies,thereby tumor cells escaping the attack of host immune system,that is the immune escape of tumor cells.Recently,new insights regard to the CD8＋ T cell exhaustion which is one of the most important mechanisms of tumor immune suppression.The CD8 ＋ T cell exhaustion is mediated by abnormal expression of T-cell immunosuppressive receptors such as PD-1 and CTLA-4.Blocking these molecules may restore the partial or all functions of T cells.This article reviewed the advances on the role of the PD-1 and CTLA-4 in hematological malignancies,including their functions on mediating T cell-immune tolerance and the progression of targeted immunotherapy,to provide the new strategy for hematological malignancies.

关 键 词：血液肿瘤 PD-1 CTLA-4 PD—L1 分子靶向治疗 

分 类 号：R733[医药卫生—肿瘤]